Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. - Wikidata - wikimedia - TriplyDB

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

http://www.wikidata.org/entity/Q40713236

about

Direct-acting antivirals for chronic hepatitis C Management of HCV-Associated Liver Cirrhosis.Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals KASL clinical practice guidelines: management of hepatitis C Daclatasvir Sofosbuvir treatment and hepatitis C virus infection A Review of Daclatasvir Drug-Drug Interactions HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis Systematic review and meta-analysis of hepatitis C virus infection and HIV viral load: new insights into epidemiologic synergy Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank Treatment optimization for HIV/HCV co-infected patients.Hepatitis C and kidney disease: A narrative review.HIV, Aging, and Viral Coinfections: Taking the Long View.Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.Daclatasvir: A Review in Chronic Hepatitis C.HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.New Therapies for Hepatitis C Virus Infection.Hepatitis C in a New Era: A Review of Current Therapies Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era.Highly Successful Hepatitis C Virus (HCV) Treatment Outcomes in Human Immunodeficiency Virus/HCV-Coinfected Patients at a Large, Urban, Ryan White Clinic.Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis.Direct-acting antivirals for chronic hepatitis C.Use of transient elastography in patients with HIV-HCV coinfection: A systematic review and meta-analysis Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the Netherlands Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea.The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations.CD4+ T-cell recovery with suppressive ART-induced rapid sequence evolution in hepatitis C virus envelope but not NS3.How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.Chronic Hepatitis C Virus Infection: A Review of Current Direct-Acting Antiviral Treatment Strategies Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy.

P2860

Q24185977-C17DF812-87EE-40F0-A15D-300817A71AE4 Q26740320-011BDC20-707A-491B-86B1-72CE686ADBC3 Q26745769-99E5D48B-60C9-4A18-8E15-42A5B231A216 Q26746563-63D24ADB-0E64-44DE-AC2E-10F0AB9D5502 Q26747561-8F4C168B-E718-4ED8-BD1A-5E84670E6A66 Q26752471-88AC4878-1E4D-4003-82AD-EDB822DD3A59 Q26769624-9A12981E-667A-4359-B010-E4F53D5A7A17 Q26770024-F802A057-D37D-468C-8371-9E3AA182F9CB Q28068712-8FDBC4AB-E0E0-4D2A-B58E-F60CEBBEE863 Q28073489-EFDA0C0F-DAB7-4AC6-A200-5DDD5EFCBBDE Q28076883-E3139AFC-1555-4632-BC2F-E2ED05F98DF8 Q28077287-23025743-89BB-4BA0-946A-3813C12756E7 Q28077305-F16798A1-7E63-40C4-A889-6A681BF95868 Q28080225-228B2B20-90E3-4467-B911-7466720B2A41 Q28553430-33830C7F-916D-4CC8-81F5-BC3BB8099D5D Q30235034-D8B420FA-AA9F-48A2-B2E9-5262B869EBB5 Q30238652-8434F525-74FF-4847-91E7-3F7579158E84 Q30245486-176C2C02-D8EF-4E61-BA98-04D6B5A0797F Q30355190-9FBC64FD-8F4C-4A2D-BA5B-3D26BEAEC09F Q30392100-BFC14C75-977D-4BE6-AD99-05898F923DA0 Q31012317-3960741A-CB6D-4F31-B86D-C7BB61892DF6 Q33557819-43A7F49F-34FC-423B-BD37-90EE951E40D6 Q33560181-9F60A891-FDDA-4F75-BD65-CFB67A7AF350 Q33585021-5CD844E6-4257-42D7-872C-2A2511A06852 Q33629538-04B6FC0D-39BB-44B0-A018-C440A19EA131 Q33647154-CD4C9BA3-FC4A-4B91-9F42-3CED38D7EF7F Q33699364-A6CD5FA1-A2E0-4838-9726-E08E7576D0F9 Q33734454-B5E16D44-7EBB-49EE-A26C-4CC59C16944D Q34557595-B1246424-027A-479E-BC2B-5657E8137553 Q35948551-F2831ADF-6176-4BC1-AD4F-4F71C6ABABE6 Q36155257-2B8C4AEA-E7FE-4053-84C5-50DEAE1DF713 Q36242517-3BE87782-12AE-4CA8-91B1-180A0E788E26 Q36243096-3F0C5D0F-E8F8-42B0-B3F3-2028B45D0E54 Q36444618-3A490739-3B88-4189-B384-24C1018F495D Q36519126-EF5BECC3-469F-48F4-AFBF-460E1B622D20 Q36619647-89026BF6-A59B-4DCB-A206-8EC2DCF2637B Q36676374-6B1FCECB-63F3-4B1C-8E74-172CD690BEDA Q36948115-89B1ADE8-BD9B-4561-A76E-FD44777E2891 Q36981033-3719F603-28B1-4485-ADFD-3A634EC89023 Q37055228-90F672EB-B9D0-40DF-8F77-5139CB01531D

P2860

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

http://www.wikidata.org/entity/Q40713236

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

@en

type

label

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

@en

prefLabel

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

@en

P1433

Q40713236-4B2A35FF-DDF0-4C28-836A-0C2D5B23CCAF

P1476

Q40713236-2D2F5F02-037C-4E4C-82F9-4BB9962B94FD

P2093

Q40713236-057FEEC4-65FA-49AC-98D8-D9EFDA898680

Q40713236-107B7D0A-7955-4AC7-9C95-589049FD5313

Q40713236-175C625F-5B8E-4B79-B14C-C62BE4318F6A

Q40713236-2F16BF41-3C55-47C8-A0E7-4004E54A03EC

Q40713236-3605E22B-94FC-46DB-98DD-A4B6A731AF71

Q40713236-4AC9B47A-3AF2-4F0C-92CB-F73FEA5573DC

Q40713236-507DDF27-94A1-4A31-80D9-94B4CD1627C1

Q40713236-55CA34C3-BB69-4B07-82BE-0357765D11B4

Q40713236-5BFE13B3-CC1C-4131-A8A5-3C801DF7DBD5

Q40713236-60BB22FF-0FAF-49E1-B538-26597833A895

P304

Q40713236-99A0A57A-970C-4CF9-B1A2-94E14FA50E37

P31

Q40713236-EB1F5822-92AF-4BE4-80EB-C636874EFE23

P356

Q40713236-9167A969-9117-4EB9-B43B-60B987A83CE1

P407

Q40713236-2424BC76-72EA-418A-97E8-7126362C431F

P433

Q40713236-13482863-70E5-4610-A50B-4BB6219EF66C

P478

Q40713236-AC2E162A-B313-4125-8084-4EC6DDC4B368

P50

Q40713236-1D246F4D-AF6B-4483-B084-729AEED29B72

Q40713236-B7ABD4FF-EABF-48B7-9744-68A588F31150

P577

Q40713236-1A713BB4-01B3-4051-87F6-C13F64C63AEE

P698

Q40713236-01B56E61-D036-4AA1-971F-DE06042BD69C

P921

Q40713236-DEC1E853-B169-4ADA-B484-B0E01D99D512

P356

P1433

The New England Journal of Medicine

P1476

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

@en

P2093

ALLY-2 Investigators

http://www.w3.org/2001/XMLSchema#string

Anthony Mills

http://www.w3.org/2001/XMLSchema#string

Anthony Scarsella

http://www.w3.org/2001/XMLSchema#string

Bruce Rashbaum

http://www.w3.org/2001/XMLSchema#string

Charles Huynh

http://www.w3.org/2001/XMLSchema#string

Cheryl McDonald

http://www.w3.org/2001/XMLSchema#string

Dawn Fishbein

http://www.w3.org/2001/XMLSchema#string

Douglas Dieterich

http://www.w3.org/2001/XMLSchema#string

Edgar Turner Overton

http://www.w3.org/2001/XMLSchema#string

Eric Hughes

http://www.w3.org/2001/XMLSchema#string

P304

714-725

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1503153

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

373

http://www.w3.org/2001/XMLSchema#string

P50

Anne F. Luetkemeyer

P577

2015-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26196502

http://www.w3.org/2001/XMLSchema#string

P921